<DOC>
	<DOCNO>NCT02195817</DOCNO>
	<brief_summary>To determine reduction alcohol consumption patient alcohol dependence treat 18 mg Selincro® as-needed use , conjunction continuous psychosocial support primary care</brief_summary>
	<brief_title>Study 18 mg Selincro® As-needed Use , Treatment Patients With Alcohol Dependence Primary Care</brief_title>
	<detailed_description>635 patient plan ( total number patient ) 475 patient treat Selincro® ( Cohort A ) 160 patient treat Selincro® ( Cohort B ) determine reduction alcohol consumption patient alcohol dependence . Cohort A comprise patient maintain high drinking risk level ( DRL , define World Health Organization ( WHO ) &gt; 60g alcohol/day man &gt; 40g alcohol/day woman ) , , period Screening Inclusion Visits . Cohort B comprise patient reduce alcohol consumption period Screening Inclusion visit , , patient maintain least high DRL Inclusion Visit ( therefore eligible treatment nalmefene accord SmPC ) .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>To ensure study broadly representative primary care clinical practice , minimal inclusion exclusion criterion impose main exclusion criterion relate contraindication prescription Selincro® reflect indication word SmPC . The patient alcohol dependence diagnose accord ICD10 . The patient high DRL 4 week precede Screening Visit . The patient man woman , age ≥18 year . The patient provide stable address telephone number . The patient one contraindication prescription Selincro® : hypersensitivity active substance excipients take opioid analgesic current recent opioid addiction acute symptom opioid withdrawal recent use opioids suspect severe hepatic impairment ( ChildPugh classification ) severe renal impairment ( eGFR &lt; 30 ml/min per 1.73 m2 ) recent history acute alcohol withdrawal syndrome ( include hallucination , seizure , delirium tremens ) The patient &lt; 6 HDDs ( define European Medicines Agency day alcohol consumption &gt; 60g men &gt; 40g woman ) 4 week precede Screening Visit . The patient physical alcohol withdrawal symptom require immediate detoxification inpatient treatment require . The patient currently participate recently ( 4 week precede Screening Visit ) participate treatment support programme alcoholuse disorder , include Alcohol Anonymous , detoxification treatment , treatment alcohol withdrawal symptom , patient already take nalmefene take nalmefene 6 month precede Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>